Ng Teng Fong General Hospital Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2014
NCT03281083
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Ng Teng Fong General Hospital

Active Ingredients

Drugs in Phase 3 Trials (4)

11c-metomidate (2 trials)

ciprofloxacin (cipro) (1 trial)

sulfamethoxazole (gantanol) (1 trial)

trimethoprim (1 trial)

Drugs in Phase 2 Trials (1)

levothyroxine (Synthroid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenoma (Phase 1)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Fatty Liver (Phase 2)

Hyperaldosteronism (Phase 1)

Hypertension (Phase 1)

Liver Diseases (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 5